OmniAb, Inc.

OABI

$4.75

-5.75%

N/A-$0.29

Healthcare

Biotechnology

NASDAQ

Active Trading

OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its ...

C-Suite Executives

(0)

The C-suite executives form a cohesive leadership team driving the company's financial strategy and innovation.

Key Team Members

No executives available for this level

Loading executive datasets...

Founder / CEO

C-Level

Board

Director / Board

Other

Key Executives

Name	Title	Compensation	Gender	Year Born	Status
Matthew W. Foehr	President, Chief Executive Officer & Director	USD 1,066,620		1973	Active
Charles S. Berkman	Chief Legal Officer	USD 742,065		1969	Active
Kurt A. Gustafson	Executive Vice President of Finance & Chief Financial Officer	USD 730,741		1968	Active
Amechi Nwachuku	Executive VP & Chief Operating Officer	—		1975	Active
Christel Iffland	Senior Vice President of R&D Portfolio Management and Technology Operations	—	—	—	Active
Bill Harriman	Senior Vice President of Discovery Partnership Mgt., Technology Development & Operations	—	—	—	Active
Todd Pettingill	Vice President of Business Development & Strategy	—		—	Active
Cia McCaffrey	Senior Vice President of People & Talent	—		—	Active
Yasmina Noubia Abdiche	Senior Vice President of Exploratory Research	—	—	—	Active
Bob Chen	Senior Vice President of Discovery Systems	—	—	—	Active

Executive Compensation

(deduped by latest filing date per person-year)

Filing Date	Year	Name	Position	Level	Salary	Bonus	Stock Award	Option Award	Incentive	Other	Total

Total Compensation Trend

Sum of disclosed compensation by year (USD million)

Key Roles Compensation Lines

Top founder/C-level executives over time (USD million)

Supply Chain of OABI

RELATIONS

Upstream

GenScript Biotech CorporationHKEx:1548 Ligand Pharmaceuticals IncorporatedNASDAQ:LGNDContract Research Organization Network (US, Europe, Asia)Laboratory Animal Breeding & Production FacilitiesThermo Fisher Scientific Inc.NYSE:TMO Illumina, Inc.NASDAQ:ILMN 10x Genomics, Inc.NASDAQ:TXG Bio-Rad Laboratories, Inc.NYSE:BIO Danaher Corporation (Cytiva)NYSE:DHR Charles River Laboratories International, Inc.NYSE:CRL Revvity, Inc. (f/k/a PerkinElmer) — BioLegendNYSE:RVTY

Downstream

Janssen Pharmaceuticals (Johnson & Johnson)NYSE:JNJTakeda Pharmaceutical Company LimitedTSE:4502Gilead Sciences, Inc.NASDAQ:GILD Sanofi S.A.NASDAQ:SNYServierBaxter International Inc.NYSE:BAX Amgen Inc.NASDAQ:AMGN Merck & Co., Inc.NYSE:MRK Pfizer Inc.NYSE:PFE AbbVie Inc.NYSE:ABBVRoche Holding AG (Genentech)SWX:ROGBristol Myers Squibb CompanyNYSE:BMYNovartis AGSWX:NOVNDana-Farber Cancer InstituteMabtrx BiosciencesWyss Institute for Biologically Inspired Engineering (Harvard University)ArrowMark Partners / Viking Global Investors (NewCo)GenScript Biotech CorporationHKEx:1548

Proxies

AbCellera Biologics Inc.NASDAQ:ABCL Regeneron Pharmaceuticals, Inc.NASDAQ:REGN Ligand Pharmaceuticals IncorporatedNASDAQ:LGND Genmab A/SNASDAQ:GMAB

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer